ISU Abxis will present its phase 1 clinical trial data for ISU104, an Erb-B2 Receptor Tyrosine Kinase 3 (ErbB3) target anti-cancer drug, at the European Society for Medical Oncology (ESMO) 2019 from Sep. 27 to Oct. 1.
The company said it plans to reveal the results of part 1 of the ISU104 phase 1 clinical trial for the first time through a poster discussion session.
“Unlike regular poster sessions displaying posters for research projects, the designation of a poster discussion session shows that the organizers saw the high potential of ISU104,” a company official said. “ISU104 is one of the research projects under the ‘Developmental Therapeutics’ program,”
Professor Kim Sung-bae of the Asan Medical Center will attend the session for questions and discussions, he added.
ISU Abxis is also preparing to conduct part 2 of phase 1 clinical trial.